SecBot SecBot
S-3/A ·Filed Nov 10, 2026

ABVC

ABVC BIOPHARMA, INC.
BEARISH
Impact 5/10
Horizonmonths Processed6d 7h ago SEC0001213900-26-118178
Shelf registration amendment
Actionable Insight ▼ Bearish

Monitor future prospectus supplements for actual pricing and size of any takedown under this shelf. The I.B.6 restriction limits near-term equity dilution but the shelf provides flexibility for debt or structured financings. Watch for any subsequent offering that would signal capital urgency given the company's going concern status.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.9921
T+0 close · Nov 10, 2026 · via day close
Latest settled
−2.87%
T+1 · $0.9636 · next T+5 tomorrow
Vs SPY
−2.52%
α at T+1
Latest observation
−6.98%
T+2 · FF3 residual α
  1. T+0 · Nov 11 $0.9921entry
  2. T+1 · 5d ago −2.87%α −2.52% · $0.9636
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ABVC BioPharma filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $100 million in securities (common stock, preferred stock, warrants, subscription rights, debt securities, and units). The filing responds to SEC comments and does not register additional securities. The company's public float was $22.2 million as of November 9, 2026, limiting primary common stock sales to one-third of that amount in any 12-month period under General Instruction I.B.6. The shelf signals potential future dilution and capital-raising flexibility for a clinical-stage biopharma with going concern risks.

Key Financial Metrics

Offering Size
$100.0M

Key Facts

  • Shelf registration of up to $100,000,000 in securities (common stock, preferred stock, warrants, subscription rights, debt securities, units).
  • Public float of $22,176,178 as of November 9, 2026, limiting primary common stock sales to one-third of public float ($7.4M) in any 12-month period.
  • 26,976,625 shares of common stock outstanding as of November 9, 2026.
  • Company is a clinical-stage biopharma with no approved products, substantial doubt about going concern, and recent financial restatements.
  • No Series A Convertible Preferred Stock has been issued as of September 30, 2026.
  • 258,710 options and 1,475,800 warrants outstanding as of the prospectus date.
  • Form of indenture for subordinated debt securities filed as exhibit 4.7; form of indenture for senior debt securities filed as exhibit 4.6.
  • Cross-filing: 10-Q filed same day (November 10, 2026) provides financial context.

Financial Impact

Up to $100,000,000 in potential securities issuance, with primary common stock sales capped at approximately $7.4M per 12 months under I.B.6 restriction.

dilutiondebtequity

Risk Factors

  • Potential dilution from future equity or convertible offerings under the shelf.
  • Company has substantial doubt about its ability to continue as a going concern, as noted in the risk factors.
  • Recent financial restatements and ineffective internal controls increase execution risk.
  • Clinical-stage pipeline with no approved products; all revenue is from licensing milestones that are uncertain.
  • Related-party transactions with director Shuling Jiang create governance risk.

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-3/A Filing (Primary)0001213900-26-118178
Document: ea0311197-s3a1_abvcbio.htm0001213900-26-118178
Document: ea031119701ex4-6.htm0001213900-26-118178

Track record

8 reports on ABVC

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +41.67% at T+60 after the Jul 2, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 424B4 Bearish 6/10 Entry $0.9700 Now $0.9400 +3.09% settles Dec 15
  2. Nov 10, 20266d ago S-3/A Bearish 5/10 Viewing Entry $0.9921 Now $0.9400 +5.25% settles Dec 10
  3. Nov 2, 202614d ago Press Release Bearish 6/10 Entry $0.9801 Now $0.9400 +4.09% settles Dec 1
  4. Nov 2, 202614d ago 8-K Bearish 6/10 Entry $0.9801 Now $0.9400 +4.09% settles Dec 1
  5. Sep 29, 20266w ago DEF 14A Bearish 6/10 Entry $1.04 to $1.05 Now $0.9400 +9.62% ▼ −0.96% −0.25% vs SPY
  6. Aug 3, 202615w ago 8-K Neutral 3/10 Entry $1.07 to $0.8254 Now $0.9400 −12.15% ▼ −22.86% −21.62% vs SPY
  7. Jul 2, 202619w ago 8-K Bearish 6/10 Entry $1.80 to $1.08 Now $0.9400 +47.78% ▲ +40.00% +39.59% vs SPY
  8. Mar 3, 202636w ago 8-K Bearish 8/10 Entry $1.45 to $1.08 Now $0.9400 +35.17% ▲ +25.52% +21.10% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 8h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026